BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
28.50
-0.10 (-0.35%)
At close: Apr 1, 2026
Market Cap166.67M -19.2%
Revenue (ttm)3.18M +161.7%
Net Income-21.83M
EPS-3.89
Shares Out5.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,396
Average Volume4,559
Open30.70
Previous Close28.60
Day's Range28.50 - 30.70
52-Week Range21.20 - 36.10
Betan/a
RSI60.37
Earnings DateMar 18, 2026

About BioVersys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ans... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 33
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

In 2025, BioVersys AG's revenue was 3.18 million, an increase of 161.75% compared to the previous year's 1.21 million. Losses were -21.83 million, 16.6% more than in 2024.

Financial Statements